Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SGMT
stocks logo

SGMT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.416
-16.75%
--
--
-0.410
-26.79%
--
--
-0.440
+37.5%
Estimates Revision
The market is revising No Change the revenue expectations for Sagimet Biosciences Inc. (SGMT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -10.69%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.81%
In Past 3 Month
Stock Price
Go Down
down Image
-10.69%
In Past 3 Month
Wall Street analysts forecast SGMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMT is 29.00 USD with a low forecast of 25.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast SGMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMT is 29.00 USD with a low forecast of 25.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.350
sliders
Low
25.00
Averages
29.00
High
35.00
Current: 6.350
sliders
Low
25.00
Averages
29.00
High
35.00
Citizens JMP
Jonathan Wolleben
Outperform
maintain
$33 -> $35
2025-11-14
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$33 -> $35
2025-11-14
maintain
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben raised the firm's price target on Sagimet Biosciences to $35 from $33 and keeps an Outperform rating on the shares. Sagimet will have first-in-human data next year for the denifanstat and resmetirom combination which could be a promising option for F4 MASH patients and its next-gen FASN inhibitor TVB-3567 which could be an effective acne treatment, the analyst tells investors in a research note. Given denifanstat's potent anti-fibrotic effects in F2/F3 patients and resmetirom's non-invasive data in cirrhotics, the combination could be compelling, the firm says.
Wedbush
NULL -> Outperform
initiated
$28
2025-08-11
Reason
Wedbush
Price Target
$28
2025-08-11
initiated
NULL -> Outperform
Reason
Wedbush initiated coverage of Sagimet Biosciences with an Outperform rating and $28 price target.
H.C. Wainwright
Brandon Folkes
initiated
$29
2025-08-07
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$29
2025-08-07
initiated
Reason
H.C. Wainwright analyst Brandon Folkes assumed coverage of Sagimet Biosciences with a Buy rating and $29 price target. The company is has a potential best-in-class fatty acid synthase inhibitor platform with "multiple shots on goal" across a number of diseases, including near-term clinical catalysts in metabolic dysfunction-associated steatohepatitis and dermatology, the analyst tells investors in a research note.
Canaccord
Edward Nash
Buy
initiated
$28
2025-07-24
Reason
Canaccord
Edward Nash
Price Target
$28
2025-07-24
initiated
Buy
Reason
Canaccord analyst Edward Nash initiated coverage of Sagimet Biosciences with a Buy rating and $28 price target.
JonesResearch
Debanjana Chatterjee
Buy
maintain
$15 -> $27
2025-06-05
Reason
JonesResearch
Debanjana Chatterjee
Price Target
$15 -> $27
2025-06-05
maintain
Buy
Reason
Oppenheimer
Outperform
to
Outperform
downgrade
$30 -> $25
2025-05-12
Reason
Oppenheimer
Price Target
$30 -> $25
2025-05-12
downgrade
Outperform
to
Outperform
Reason
Oppenheimer lowered the firm's price target on Sagimet Biosciences to $25 from $30 and keeps an Outperform rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Sagimet Biosciences Inc (SGMT.O) is -3.56, compared to its 5-year average forward P/E of -2.62. For a more detailed relative valuation and DCF analysis to assess Sagimet Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.62
Current PE
-3.56
Overvalued PE
-1.02
Undervalued PE
-4.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.19
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.50
Undervalued EV/EBITDA
-0.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.61
Current PS
0.00
Overvalued PS
39.41
Undervalued PS
-26.20
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SGMT News & Events

Events Timeline

(ET)
2025-11-13
07:34:13
Sagimet Biosciences Announces Q3 Earnings Per Share of 40 Cents, Exceeding Consensus Estimate of 39 Cents
select
2025-11-10 (ET)
2025-11-10
07:54:55
Sagimet Biosciences Unveils Two Posters on Denifanstat at AASLD
select
2025-10-24 (ET)
2025-10-24
07:03:34
Sagimet Biosciences reports that denifanstat achieved all primary and secondary endpoints.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-26TipRanks
Top Analysts Recommend 3 Best Stocks to Purchase Now, 11/26/2025

  • Top Stock Picks: Three companies have received Strong Buy ratings from top Wall Street analysts, indicating significant upside potential for investors.

  • Analyst Tools: TipRanks offers an Analyst Top Stocks tool that tracks real-time Buy ratings from high-performing analysts, helping investors make informed decisions.

  • Analyst Rankings: Financial analysts are ranked by TipRanks based on their rating success rates and average returns, with top analysts achieving five-star rankings for their accuracy and profitability.

  • Research Resources: Investors are encouraged to thoroughly research stocks before adding them to their portfolios, utilizing resources like TipRanks’ Top Wall Street Analysts page for real-time insights.

[object Object]
Preview
9.5
11-13Newsfilter
Sagimet Biosciences Announces Financial Results for Q3 2025 and Shares Corporate Updates

  • Clinical Trials Update: Sagimet Biosciences is conducting a Phase 1 clinical trial to evaluate the pharmacokinetics of a combination of denifanstat and resmetirom, with data expected in the first half of 2026. Additionally, a first-in-human Phase 1 trial for the FASN inhibitor TVB-3567 is underway.

  • Regulatory Progress: Ascletis Pharma has completed its pre-NDA consultation with China's NMPA and plans to submit an NDA for denifanstat for treating moderate-to-severe acne vulgaris.

  • Financial Performance: For the quarter ending September 30, 2025, Sagimet reported a net loss of $12.9 million, with cash and marketable securities totaling $125.5 million.

  • Future Milestones: Sagimet anticipates starting a Phase 2 clinical trial for moderate to severe acne patients in 2026, contingent on the outcomes of ongoing trials and regulatory consultations.

[object Object]
Preview
9.0
10-24SeekingAlpha
Sagimet's Stock Increases Following Successful Late-Stage Trial of Denifanstat

  • Positive Trial Results: Sagimet Biosciences announced successful results from a late-stage trial of denifanstat for moderate to severe acne vulgaris, achieving all primary and secondary objectives.

  • Significant Improvements: At the 12-week mark, patients treated with denifanstat showed treatment success rates more than double that of the placebo group, with notable improvements in both inflammatory and non-inflammatory acne lesions.

  • Well Tolerated: The treatment was well tolerated by participants, contributing to the positive outlook for denifanstat.

  • Stock Market Reaction: Following the announcement of the trial results, Sagimet Biosciences' stock rose approximately 6.3%.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Sagimet Biosciences Inc (SGMT) stock price today?

The current price of SGMT is 6.35 USD — it has decreased -1.7 % in the last trading day.

arrow icon

What is Sagimet Biosciences Inc (SGMT)'s business?

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

arrow icon

What is the price predicton of SGMT Stock?

Wall Street analysts forecast SGMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMT is 29.00 USD with a low forecast of 25.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Sagimet Biosciences Inc (SGMT)'s revenue for the last quarter?

Sagimet Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Sagimet Biosciences Inc (SGMT)'s earnings per share (EPS) for the last quarter?

Sagimet Biosciences Inc. EPS for the last quarter amounts to -0.40 USD, decreased -11.11 % YoY.

arrow icon

What changes have occurred in the market's expectations for Sagimet Biosciences Inc (SGMT)'s fundamentals?

The market is revising No Change the revenue expectations for Sagimet Biosciences Inc. (SGMT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -10.69%.
arrow icon

How many employees does Sagimet Biosciences Inc (SGMT). have?

Sagimet Biosciences Inc (SGMT) has 14 emplpoyees as of December 05 2025.

arrow icon

What is Sagimet Biosciences Inc (SGMT) market cap?

Today SGMT has the market capitalization of 206.51M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free